VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ 18 years of age or older                           │ 18 years of age or older                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be capable and willing to provide written informed │ Be capable and willing to provide written informed │     100 │
│ consent to participate in this study               │ consent to participate in this study               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agree to abide by the study protocol and its       │ Agree to abide by the study protocol and its       │     100 │
│ restrictions and be able to complete all aspects   │ restrictions and be able to complete all aspects   │         │
│ of the study, including all visits and tests       │ of the study, including all visits and tests       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients posing a serious suicidal risk and/or     │ Patients posing a serious suicidal risk and/or     │     100 │
│ violence as judged by the investigator             │ violence as judged by the investigator             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Delirium                                           │ Delirium                                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Dementia                                           │ Dementia                                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Amnestic and other cognitive disorder              │ Amnestic and other cognitive disorder              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of hypothyroidism unless   │ Patients with a history of hypothyroidism unless   │     100 │
│ taking a stable dose of thyroid medication and     │ taking a stable dose of thyroid medication and     │         │
│ asymptomatic or euthyroid for 6 months             │ asymptomatic or euthyroid for 6 months             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ hepatic insufficiency (three times the upper limit │ hepatic insufficiency (three times the upper limit │     100 │
│ of normal (ULN) for aspartate aminotransferase     │ of normal (ULN) for aspartate aminotransferase     │         │
│ (AST) and/or alanine aminotransferase (ALT));      │ (AST) and/or alanine aminotransferase (ALT));      │         │
│ liver transplant recipient; cirrhosis of the liver │ liver transplant recipient; cirrhosis of the liver │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ malignancy (except basal cell carcinoma) and/or    │ malignancy (except basal cell carcinoma) and/or    │     100 │
│ chemotherapy within 1 year prior to screening;     │ chemotherapy within 1 year prior to screening;     │         │
│ malignancy more than 1 year prior to screening     │ malignancy more than 1 year prior to screening     │         │
│ must have been local and without metastasis and/or │ must have been local and without metastasis and/or │         │
│ recurrence, and if treated with chemotherapy,      │ recurrence, and if treated with chemotherapy,      │         │
│ without nervous system complications               │ without nervous system complications               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ significant unstable medical condition or life     │ significant unstable medical condition or life     │     100 │
│ threatening disease with anticipated survival of   │ threatening disease with anticipated survival of   │         │
│ less than 6 months                                 │ less than 6 months                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ need for therapies that may obscure the results of │ need for therapies that may obscure the results of │     100 │
│ treatment and/or of the study                      │ treatment and/or of the study                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial within 30  │ Participation in another clinical trial within 30  │     100 │
│ days of the screening visit                        │ days of the screening visit                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticipated inability to attend scheduled study    │ Anticipated inability to attend scheduled study    │     100 │
│ visits                                             │ visits                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who in the judgment of the Investigator   │ Patients who in the judgment of the Investigator   │     100 │
│ may be unreliable or uncooperative with the        │ may be unreliable or uncooperative with the        │         │
│ evaluation procedure outlined in this protocol     │ evaluation procedure outlined in this protocol     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of prior pharmacogenomic   │ Patients with a history of prior pharmacogenomic   │     100 │
│ testing                                            │ testing                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any change in psychotropic medication (including   │ Any change in psychotropic medication (including   │     100 │
│ change in dosage) between screening and baseline   │ change in dosage) between screening and baseline   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are known to be pregnant or lactating │ Patients who are known to be pregnant or lactating │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of gastric bypass surgery  │ Patients with a history of gastric bypass surgery  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who meet DSM-IV-TR criteria for any       │ Patients who meet DSM-IV-TR criteria for any       │      92 │
│ significant current substance dependence           │ significant current substance abuse                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ 18 years of age or older                           │      42 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with                                      │ Patients with a history of gastric bypass surgery  │      42 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have moderate to severe psychiatric symptoms       │ Have a total baseline score on the Brief           │      46 │
│                                                    │ Psychiatric Rating Scale (BPRS) = 45               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are on restricted diets (e.g.,        │ Patients who in the judgment of the Investigator   │      46 │
│ diabetes), who have an eating restriction disorder │ may be unreliable or uncooperative with the        │         │
│ (e.g., bulimia, anorexia), or who are undergoing   │ evaluation procedure outlined in this protocol     │         │
│ weight-reducing interventions (e.g. metformin, or  │                                                    │         │
│ structured diet program)                           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intending to switch to, or start a new             │ Patients with a history of prior pharmacogenomic   │      49 │
│ antipsychotic medication                           │ testing                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a current Axis I diagnosis of        │ Patients with a history of prior pharmacogenomic   │      55 │
│                                                    │ testing                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Suffer from schizophrenia, schizoaffective         │ Suffer from schizophrenia/schizoaffective disorder │      72 │
│ disorder, schizophreniform disorder, psychosis not │ meeting Diagnostic and Statistical Manual of       │         │
│ otherwise specified, bipolar disorder (I, II, NOS) │ Mental Disorders, Fourth Edition, Text Revision    │         │
│ or major depressive disorder meeting Diagnostic    │ (DSM-IV-TR) criteria                               │         │
│ and Statistical Manual of Mental Disorders, Fourth │                                                    │         │
│ Edition, Text Revision (DSM-IV-TR) criteria        │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Have moderate to severe psychiatric symptoms       │ Have a total baseline score on the Brief           │      46 │
│                                                    │ Psychiatric Rating Scale (BPRS) = 45               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Suffer from schizophrenia, schizoaffective         │ Suffer from schizophrenia/schizoaffective disorder │      72 │
│ disorder, schizophreniform disorder, psychosis not │ meeting Diagnostic and Statistical Manual of       │         │
│ otherwise specified, bipolar disorder (I, II, NOS) │ Mental Disorders, Fourth Edition, Text Revision    │         │
│ or major depressive disorder meeting Diagnostic    │ (DSM-IV-TR) criteria                               │         │
│ and Statistical Manual of Mental Disorders, Fourth │                                                    │         │
│ Edition, Text Revision (DSM-IV-TR) criteria        │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 88
Average Levenshtein Ratio of individual lines: 84.89655172413794
OverAll Ratio: 86.44827586206897
